Sodium-glucose cotransporter inhibition: Therapeutic potential for the treatment of type 2 diabetes mellitus

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 5, 2013, Pages 347-356

  Raskin, Philip ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Glucose reabsorption; Sodium glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; BI 44847; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; INSULIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; LX 4211; METFORMIN; MOLECULE TRANSPORT AGENT; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA; TOFOGLIFLOZIN; UNCLASSIFIED DRUG;

ADD ON THERAPY; BACKACHE; BRONCHITIS; DIARRHEA; DRUG DOSE TITRATION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; FUNGAL GENITAL INFECTION; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

GLUCOSE REABSORPTION; SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR; TYPE 2 DIABETES MELLITUS;

ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MEMBRANE TRANSPORT MODULATORS; MOLECULAR TARGETED THERAPY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84880012343     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2403     Document Type: Review

References (80)

1. Singleton JR, Smith AG, Russell JW, Feldman EL. Microvascular complications of impaired glucose tolerance. Diabetes 2003; 52: 2867-2873.
2. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18: 2644-2648.
3. Centers for Disease Control and Prevention. US obesity trends. Available at: http://www.cdc.gov/obesity/data/trends.html. Accessed December 14, 2012.
4. Fox CS, Coady S, Sorlie PD, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007; 115: 1544-1550.
5. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13, 000 men and women with 20years of follow-up. Arch Intern Med 2004; 164: 1422-1426.
6. UKPDS 34. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
7. UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
8. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
10. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes: results and projections from the Steno-2 Study. N Engl J Med 2008; 358: 580-591.
11. Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009; 122: 443-453.
12. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005; 28: 600-606.
13. Wetzler HP, Snyder JW. Linking pharmacy and laboratory data to assess the appropriateness of care in patients with diabetes. Diabetes Care 2000; 23: 1637-1641.
14. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med 2008; 23: 588-594.
15. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836-1841.
16. Lau DT, Nau DP. Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes. Diabetes Care 2004; 27: 2149-2153.
17. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 2004; 27: 384-391.
18. Walker EA, Molitch M, Kramer MK, et al. Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program. Diabetes Care 2006; 29: 1997-2002.
19. Kocurek B. Promoting medication adherence in older adults ...and the rest of us. Diabetes Spectrum 2009; 22: 80-84.
20. Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in type 2 diabetes. Diabet Med 2008; 25: 245-254.
21. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009; 32: S151-S156.
22. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
23. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
24. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17: 1-53.
25. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
26. Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001; 24: 382-391.
27. Ferrannini E. Learning from glycosuria. Diabetes 2011; 60: 695-696.
28. Hediger MA, Kanai Y, You G, Nussberger S. Mammalian ion-coupled solute transporters. J Physiol 1995; 482: 7S-17S.
29. Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diabetes Ther 2010; 1: 57-92.
30. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011; 22: 104-112.
31. Lee WS, Kanai Y, Wells RG, Hediger MA. The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression. J Biol Chem 1994; 269: 12032-12039.
32. Calado J, Santer R, Rueff J. Effect of kidney disease on glucose handling (including genetic defects). Kidney Int Suppl 2011; 79: S7-S13.
33. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005; 54: 3427-3434.
34. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev 2005; 21: 31-38.
35. Kahn BB, Shulman GI, DeFronzo RA, Cushman SW, Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991; 87: 561-570.
36. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987; 79: 1510-1515.
37. White JR. Apple trees to sodium glucose co-transporter inhibitors: a review of SGLT2 inhibition. Clin Diabetes 2010; 28: 5-10.
38. Goldring W, Welsh C. The effects on renal activity of the oral administration of phlorizin in man. J Clin Invest 1934; 13: 749-752.
39. Ferrannini E. Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant 2010; 25: 2041-2043.
40. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33: 2217-2224.
41. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
42. Strojek K, Yoon KH, Hruba V, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011; 13: 928-938.
43. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-1478.
44. Wilding JPH, Woo V, Soler NG, et al. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin. Ann Intern Med 2012; 156: 405-415.
45. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97: 1020-1031.
46. Salsali A, Rohwedder K, Mansfield T, et al. Durability of dapagliflozin treatment response in patients with T2DM: 2-year results [abstract]. Diabetes 2012; 61: A264.
47. Wilding JPH, Woo V, Rohwedder K, Sugg J, Parikh S. Long-term effectiveness of dapagliflozin over 104weeks in patients with type 2 diabetes poorly controlled with insulin [abstract]. Diabetes 2012; 61: A267.
48. Jabbour S, Hardy E, Sugg JE, Parikh S. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a randomized, double-blind, placebo-controlled study [abstract]. Diabetes 2012; 61: A275.
49. Henry RR, Murray AV, Marmolejo MH, et al. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract 2012; 66: 446-456.
50. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
51. Cefalu WT, Leiter LA, DeBruin TW, et al. Dapagliflozin treatment for type 2 diabetes mellitus patients with cormorbid cardiovascular disease and hypertension [abstract]. Diabetes 2012; 61: A271.
52. Leiter LA, Cefalu WT, DeBruin TW, et al. Efficacy and safety of dapagliflozin for type 2 diabetes mellitus patients with a history of cardiovascular disease. Diabetes 2012; 61: A287.
53. Kohan DE, Fioretto P, List J, Tang W. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstract]. J Am Soc Nephrol 2011; 22: 232A.
54. List J, Ley S, Ptaszynska A, et al. Characterization of genital infections in the setting of pharmacologically induced glucosuria [abstract]. Diabetes Metab 2011; 60: A270.
55. Parikh SJ, Johnsson KM, Ptaszynska A, et al. Characterization of urinary tract infections in the setting of pharmacologically induced glucosuria [abstract]. Diabetes 2011; 60: A270.
56. Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 2011; 10: 645-646.
57. Ptaszynska A, Johnsson KM, Apanovitch AM, et al. Safety of dapagliflozin in clinical trials for T2DM [abstract]. Diabetes 2012; 61: A258.
58. AstraZeneca and Bristol-Myers Squibb receive complete response letter from US Food and Drug Administration for dapagliflozin. Available at: http://www.astrazeneca.com/Media/Press-releases/Article/19012012--AstraZeneca-Bristol-Myers-Squibb-receive-CRL-for-dapagliflozin. Accessed October 31, 2012.
59. European Medicines Agency. Marketing authorization for dapagliflozin. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002322/human_med_001546.jsp&mid=WC0b01ac058001d124. Accessed January 10, 2013.
60. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372-382.
61. Wilding JP, Mathieu C, Vercruysse F, et al. Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU) [abstract]. Diabetes 2012; 61: A262.
62. Cefalu WT, Leiter LA, Niskanen L, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [abstract]. Diabetes 2012; 61: LB10.
63. Matthew D, Fulcher GR, Perkovic V, et al. Efficacy and safety of canagliflozin, an inhibitor of sodium glucose co-transporter 2, added on to insulin therapy with or without oral agents in type 2 diabetes. Presented at: European Association for the Study of Diabetes; October 1-5, 2012; Berlin, Germany.
64. Gross JL, Schernthaner G, Fu M, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor: compared with sitagliptin in patients with type 2 diabetes on metfromin plus sulfonylurea [abstract]. Diabetes 2012; 61: LB13.
65. Yale J-F, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013; doi:10.1111/dom.12090
66. Bode B, Stenlof K, Sullivan D, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in older subjects with type 2 diabetes mellitus. Presented at: European Association for the Study of Diabetes; October 1-5, 2012; Berlin, Germany.
67. Janssen. Janssen Research & Development submits New Drug Application to U.S. FDA for canagliflozin to treat patients with type 2 diabetes. Available at: http://www.jnj.com/connect/news/all/janssen-research-development-submits-new-drug-application-to-us-fda-for-canagliflozin-to-treat-patients-with-type-2-diabetes. Accessed October 31, 2012.
68. Janssen. Janssen submits European Marketing Authorisation application for canagliflozin in type 2 diabetes. Available at: http://www.jnj.com/connect/news/all/janssen-submits-european-marketing-authorisation-application-for-canagliflozin-in-type-2-diabetes. Accessed October 31, 2012.
69. FDA advisory committee recommends approval of canagliflozin for treatment of adults with type 2 diabetes. Available at: http://www.jnj.com/connect/news/all/fda-advisory-committee-recommends-approval-of-canagliflozin-for-treatment-of-adults-with-type-2-diabetes. Accessed January 11, 2013.
70. Ferrannini E, Seman LJ, Seewaldt-Becker E, et al. The potent and highly selective sodium-glucose co-transporter (SGLT-2) inhibitor BI10773 is safe and efficacious as monotherapy in patients with type 2 diabetes mellitus [abstract]. Diabetologia 2010; 53: S351.
71. Woerle HJ, Ferrannini E, Berk A, et al. Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes [abstract]. Diabetes 2012; 61: LB13.
72. Rosenstock J, Jelaska A, Seman L, et al. Efficacy and safety of BI 10773, a new sodium glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes inadequately controlled on metformin [abstract]. Diabetes 2011; 60: A271.
73. Goto K, Kashiwagi A, Kazuta K, et al. Ipragliflozin reduces A1C and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: ILLUMINATE study [abstract]. Diabetes 2012; 61: A269.
74. Freiman J, Ruff DA, Frazier KS, et al. LX4211, a dual SGLT2/SGLT1 inhibitor, shows rapid and significant improvement in glycemic control over 28days in patients with type 2 diabetes (T2DM) [abstract]. Diabetes 2010; 59: LB6.
75. Nucci G, Amin NB, Wang X, Lee DS, Rusnak JM. The sodium glucose co-transporter-2 (SGLT2) inhibitor, PF04971729, provides multi-faceted improvements in diabetic patients inadequately controlled on metformin [abstract]. Diabetologia 2011; 54: S347.
76. Seino Y, Sasaki T, Fukatsu A, et al. TS-071, a novel and selective SGLT2 inhibitor, improved glycemic control and decreased body weight in 12-week study of Japanese patients with type 2 diabetes mellitus [abstract]. Diabetes 2011; 60: 0998-P.
77. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41: 281-288.
78. Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26: 510-513.
79. Hoepelman AIM, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents 2003; 22: s35-s43.
80. Nauck M, Del Prato S, Rohwedder K, et al. Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizide in patients with T2DM inadequately controlled with metformin: 2-year results [abstract]. Diabetes 2011; 60: LB12.